Literature DB >> 31371896

Association of Serum Copeptin Levels with Patency of Infarct-Related Arteries in Patients with ST-Segment Elevation Myocardial Infarction.

Birsen Doganay1, Sercan Okutucu2, Mustafa Cetin1, Emrullah Kızıltunc1, Orhan Karayigit1, Can Ozkan1, Muhammed Fevzi Kılınckaya3, Ender Ornek1.   

Abstract

BACKGROUND: Copeptin is widely used as a predictor of an adverse prognosis in many clinical conditions. Reduced antegrade coronary flow in an infarct-related artery (IRA) is associated with adverse clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to investigate whether copeptin level on admission was associated with IRA patency in STEMI patients.
METHODS: A total of 88 patients were enrolled into the study and divided into two groups according to TIMI flow grade in the IRA before primary percutaneous coronary intervention.
RESULTS: White blood cell count (p = 0.015), neutrophils (p = 0.047), N-terminal pro-brain natriuretic peptide (NTproBNP) (p < 0.001), copeptin (p < 0.001) and peak troponin I (p = 0.001) were significantly higher in the occluded IRA group with a significantly lower serum sodium level (p < 0.001). Age- and gender-adjusted multivariate analysis revealed that copeptin (OR = 1.970; p = 0.001), peak troponin I (1.055; p = 0.005) and NTproBNP (OR = 1.003; p = 0.010) were independent predictors of an occluded IRA. A copeptin cut-off value of > 6.8 ng/mL was found to predict an occluded IRA with a sensitivity of 80% and specificity of 100% (area under the curve: 0.917; p < 0.001). Performance ranking of the biomarkers that could predict an occluded IRA showed copeptin > peak troponin I = NTproBNP.
CONCLUSIONS: Copeptin levels were higher in the patients with an occluded IRA and STEMI. Higher levels of copeptin predicted an occluded IRA in the patients with STEMI who were admitted to the emergency department during the first three hours of chest pain.

Entities:  

Keywords:  Copeptin; Infarct-related artery; Myocardial infarction; Patency; STEMI

Year:  2019        PMID: 31371896      PMCID: PMC6656972          DOI: 10.6515/ACS.201907_35(4).20181101A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  33 in total

1.  Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials.

Authors:  G W Stone; D Cox; E Garcia; B R Brodie; M C Morice; J Griffin; L Mattos; A J Lansky; W W O'Neill; C L Grines
Journal:  Circulation       Date:  2001-08-07       Impact factor: 29.690

2.  Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction.

Authors:  B R Brodie; T D Stuckey; C Hansen; D Muncy
Journal:  Am J Cardiol       Date:  2000-01-01       Impact factor: 2.778

3.  Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.

Authors:  Nils G Morgenthaler; Joachim Struck; Christine Alonso; Andreas Bergmann
Journal:  Clin Chem       Date:  2005-11-03       Impact factor: 8.327

4.  Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction.

Authors:  Gjin Ndrepepa; Adnan Kastrati; Markus Schwaiger; Julinda Mehilli; Christina Markwardt; Alban Dibra; Josef Dirschinger; Albert Schömig
Journal:  J Nucl Med       Date:  2005-11       Impact factor: 10.057

5.  Copeptin: clinical use of a new biomarker.

Authors:  Nils G Morgenthaler; Joachim Struck; Stefan Jochberger; Martin W Dünser
Journal:  Trends Endocrinol Metab       Date:  2008-03       Impact factor: 12.015

6.  Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level.

Authors:  Mira Katan; Nils Morgenthaler; Isabelle Widmer; Jardena J Puder; Caroline König; Beat Müller; Mirjam Christ-Crain
Journal:  Neuro Endocrinol Lett       Date:  2008-06       Impact factor: 0.765

7.  Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty.

Authors:  Giuseppe De Luca; Nicolette Ernst; Felix Zijlstra; Arnoud W J van 't Hof; Jan C A Hoorntje; Jan-Henk E Dambrink; A T Marcel Gosslink; Menko-Jan de Boer; Harry Suryapranata
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

8.  Peak CKMB and cTnT accurately estimates myocardial infarct size after reperfusion.

Authors:  Erik Hedström; Karin Aström-Olsson; Hans Ohlin; Fredrik Frogner; Marcus Carlsson; Therese Billgren; Stefan Jovinge; Peter Cain; Galen S Wagner; Håkan Arheden
Journal:  Scand Cardiovasc J       Date:  2007-01       Impact factor: 1.589

9.  Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock.

Authors:  Nils G Morgenthaler; Beat Müller; Joachim Struck; Andreas Bergmann; Heinz Redl; Mirjam Christ-Crain
Journal:  Shock       Date:  2007-08       Impact factor: 3.454

10.  C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.

Authors:  Sohail Q Khan; Onkar S Dhillon; Russell J O'Brien; Joachim Struck; Paulene A Quinn; Nils G Morgenthaler; Iain B Squire; Joan E Davies; Andreas Bergmann; Leong L Ng
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690

View more
  2 in total

1.  Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.

Authors:  Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

2.  Clinical, Demographic, and Biochemical Characteristics of Patients with Acute ST-Segment Elevation Myocardial Infarction: An Analysis of Acute Coronary Syndrome Registry Data of a Single Medical Center from 2005 to 2016.

Authors:  Chun-Chung Lin; Pei-Yu Lee; Kuo-Chin Chen; Pen-Chih Liao; Jung-Cheng Hsu; Ai-Hsien Li
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.